ConductScience.org, home
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
API referenceFor AI assistants

Trial · NCT03556202

Participant flow30

How many started, completed or left each group, period by period.

1 to 20 of 30

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Extension Treatment PeriodSTARTED125 Milligram (mg) Mirikizumab Q8W527
Extension Treatment PeriodSTARTED250 mg Mirikizumab Q8W Excluding Secukinumab1,020
Extension Treatment PeriodSTARTEDSecukinumab/250 mg Mirikizumab Q8W389
Extension Treatment PeriodReceived at Least One Dose of Study Drug125 Milligram (mg) Mirikizumab Q8W527
Extension Treatment PeriodReceived at Least One Dose of Study Drug250 mg Mirikizumab Q8W Excluding Secukinumab1,020
Extension Treatment PeriodReceived at Least One Dose of Study DrugSecukinumab/250 mg Mirikizumab Q8W389
Extension Treatment PeriodFrom AMAF125 Milligram (mg) Mirikizumab Q8W35
Extension Treatment PeriodFrom AMAF250 mg Mirikizumab Q8W Excluding Secukinumab132
Extension Treatment PeriodFrom AMAFSecukinumab/250 mg Mirikizumab Q8W0
Extension Treatment PeriodFrom AMAK125 Milligram (mg) Mirikizumab Q8W83
Extension Treatment PeriodFrom AMAK250 mg Mirikizumab Q8W Excluding Secukinumab390
Extension Treatment PeriodFrom AMAKSecukinumab/250 mg Mirikizumab Q8W0
Extension Treatment PeriodFrom AMAJ125 Milligram (mg) Mirikizumab Q8W409
Extension Treatment PeriodFrom AMAJ250 mg Mirikizumab Q8W Excluding Secukinumab498
Extension Treatment PeriodFrom AMAJSecukinumab/250 mg Mirikizumab Q8W389
Extension Treatment PeriodCOMPLETED125 Milligram (mg) Mirikizumab Q8W0
Extension Treatment PeriodCOMPLETED250 mg Mirikizumab Q8W Excluding Secukinumab0
Extension Treatment PeriodCOMPLETEDSecukinumab/250 mg Mirikizumab Q8W0
Extension Treatment PeriodNOT COMPLETED125 Milligram (mg) Mirikizumab Q8W527
Extension Treatment PeriodNOT COMPLETED250 mg Mirikizumab Q8W Excluding Secukinumab1,020

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03556202/flow

API referenceFor AI assistants